Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Formac Pharmaceuticals from Leuven, company number BE0892914395, closed financial year 2025 with a result of € 1,622 after tax. For that financial year Formac Pharmaceuticals recorded a gross margin of € 2,644 and equity of € 2,112. Compared with financial year 2024, the result moved from € -28,882 to € 1,622. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 2,112
▲ € 1,622 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1,622
▲ still € 28,882 loss in 2024
Profit after tax over the fiscal year.
€ 1,835
▲ € 1,625 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -6.9 million.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -3,908 | € -6,758 | € 145,623 | € 2,644 | ▼ 98% |
| Profit after taxes | € -130,323 | € -132,501 | € -28,882 | € 1,622 | ▲ € 30,504 |
| Equity | € 161,872 | € 29,371 | € 489 | € 2,112 | ▲ € 1,622 |
| Total debts | € 148,217 | € 156,189 | € 0 | € 0 | |
| Cash | € 10,896 | € 4,613 | € 211 | € 1,835 | ▲ € 1,625 |
| Retained profit | € -6,725,731 | € -6,858,232 | € -6,887,114 | € -6,885,492 | |
| Bank debt | € 100,000 | € 100,000 | € 0 | € 0 | |
| Balance sheet total | € 310,090 | € 185,561 | € 489 | € 2,112 | ▲ € 1,622 |
Key figures of Formac Pharmaceuticals, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Formac Pharmaceuticals?
What happened at Formac Pharmaceuticals in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1,622. Source: NBB ↗
- New establishment in Leuven. KBO
- Start of the company according to the CBE. KBO
In short
From € 130,323 loss in 2022 to € 1,622 profit in 2025.
Best year ever: 2025, with € 1,622 profit.
A new publication or filing at Formac Pharmaceuticals? We notify you, reason included.
Follow Formac PharmaceuticalsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Allegro Investment Fund, GEMMA FRISIUS-FONDS KU LEUVEN comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Formac PharmaceuticalsBehind Formac Pharmaceuticals are Rudi Cuyvers, Johan Martens and Ivo Roelants. The shares are held by Allegro Investment Fund (15.9%) and GEMMA FRISIUS-FONDS KU LEUVEN.
Directors
According to the 2025 annual accounts
Rudi Cuyvers
Director
Also active at: TRANSPORT & MOBILITY LEUVEN, MatchID, Hammer-IMS, ZB Sports Development, MAGNETS FOR EMULSIONS, Atmire
Ivo Roelants
Director
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 1
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →reMYND
€ -217,249 gross margin · 2025
DName-iT
€ -71,430 gross margin · 2025
miDiagnostics
€ 24,934 revenue · 2025
ALIGOS BELGIUM
€ 3.2 million gross margin · 2025
Pledge Therapeutics
€ -97,474 gross margin · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0892.914.395
- VAT number
- BE 0892.914.395
- Registered office
- Gaston Geenslaan 1, 3001 Leuven
- Names & denominations
- Formac Pharmaceuticals
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 3 October 2007
- Peppol
- Active · Active since 13 Aug 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van overige farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Vervaardiging van overige farmaceutische preparaten
Groothandel in farmaceutische producten